Adenomyosis treatment ranges from over-the-counter painkillers for mild symptoms all the way to hysterectomy for severe, refractory disease, with a widening set of hormonal therapies and uterine-sparing procedures in between. The right approach depends on how much pain and bleeding you have, whether you want to preserve fertility, and how close you are to menopause. No single drug cures adenomyosis, but several can substantially shrink the uterus, cut pain scores by more than half, and buy years of symptom control.
Pain Relief and Bleeding Control Without Hormones
If your symptoms are mild or flare up occasionally between other treatments, two non-hormonal options are typically tried first. NSAIDs like ibuprofen or naproxen reduce menstrual cramp intensity by lowering prostaglandin production in the uterus, while tranexamic acid helps slow heavy menstrual bleeding by preventing clots from breaking down too quickly. Neither targets the underlying disease. A 2023 review of medical therapies for adenomyosis characterized both as offering “limited support for mild symptoms or symptom re-exacerbation during hormone therapy,” meaning they work best as add-ons rather than standalone treatments.1PubMed Central. Current Medical Therapy for Adenomyosis: From Bench to Bedside If you find yourself relying on high-dose NSAIDs every cycle just to function, that is a strong signal to discuss hormonal or procedural options with your doctor.
The Levonorgestrel Intrauterine Device
The levonorgestrel-releasing intrauterine device, often known by the brand name Mirena, is one of the most studied first-line hormonal treatments for adenomyosis. It delivers a small, steady dose of progestin directly into the uterine lining, which thins the endometrium, reduces bleeding, and eases pain without requiring you to remember a daily pill. In a study comparing adenomyosis subtypes, pain scores and measured blood loss dropped significantly in all groups after insertion.2PubMed Central. Efficacy of the levonorgestrel-releasing intrauterine device is associated with different subtypes of adenomyosis: a retrospective study Separate research found that the device improved bleeding duration, menstrual pain, and hemoglobin levels at both one month and twelve months in women with adenomyosis.3PubMed. Effects of levonorgestrel-releasing intrauterine system and T380A intrauterine copper device on dysmenorrhea and days of bleeding in women with and without adenomyosis
One practical concern is that a significantly enlarged uterus can distort the uterine cavity enough to increase the risk of IUD expulsion. If your uterus is very large, your doctor may suggest shrinking it first with a short course of another drug before placing the device, or may recommend a different treatment altogether. For women with a moderately enlarged uterus, though, the hormonal IUD remains a strong option because it works locally, produces fewer systemic side effects than oral medications, and lasts up to five years.
Oral Hormonal Medications
Dienogest, a progestin taken as a daily pill, has become one of the most widely prescribed oral treatments for adenomyosis outside the United States. A meta-analysis found that dienogest reduced dysmenorrhea scores by an average of six points on a ten-point scale, and patients with worse baseline pain and longer treatment durations saw even larger improvements.4European Journal of Obstetrics & Gynecology and Reproductive Biology. Dienogest treatment of symptomatic adenomyosis: An in-depth meta-analysis In a clinical study, roughly 80% of women reported improved menstrual pain and about 88% saw their heavy bleeding get better, with uterine volume shrinking significantly after 18 months.5PubMed Central. Clinical Efficacy of Dienogest for Symptomatic Adenomyosis
The tradeoff is that dienogest must be taken continuously, and symptoms tend to return once you stop. In that same study, about a third of patients discontinued or switched therapies. In perimenopausal women specifically, dienogest showed strong long-term results: average pain scores dropped from about 7 out of 10 at baseline to under 2 within six months, and many women stayed on the drug for over two years with good symptom control.6Scientific Reports. Long-term clinical outcomes of dienogest for perimenopausal women with symptomatic adenomyosis For women approaching menopause, dienogest can serve as a bridge therapy, controlling symptoms until natural estrogen decline takes over.
Combined oral contraceptive pills are sometimes used off-label, often in a continuous regimen that skips the placebo week to suppress menstruation entirely. Evidence specifically for adenomyosis is thinner than for dienogest, but continuous combined pills can reduce pain and bleeding in women with milder disease who also want contraception.
GnRH Drugs and Aromatase Inhibitors
When first-line hormonal therapies are not enough, a second tier of drugs can more aggressively suppress the hormonal environment that fuels adenomyosis. GnRH agonists (such as leuprolide) and the newer GnRH antagonist relugolix both work by dramatically lowering estrogen, which shrinks the uterus and relieves pain. In a study of 46 women with confirmed adenomyosis treated with a GnRH agonist, mean uterine volume fell from about 295 cm³ to roughly 184 cm³.7Biomedical and Pharmacology Journal. Extended GnRH Agonist and NETA Add-Back: An Effective and Safe Option for Refractory Endometriosis/Adenomyosis Pain Relugolix, an oral GnRH antagonist, showed even more dramatic results in a separate study: uterine volume was roughly halved, and all 30 patients experienced resolution of heavy bleeding, menstrual pain, or chronic pelvic pain.8Journal of Endometriosis and Pelvic Pain Disorders. Gonadotropin-releasing hormone antagonist (relugolix) for treatment of uterine adenomyosis with symptomatic endometriosis
The catch is that sustained estrogen suppression causes menopausal side effects: hot flashes, bone density loss, mood changes. To blunt these, doctors often prescribe hormonal “add-back therapy,” a low dose of estrogen and progestin that keeps your bones and symptoms manageable without reactivating the adenomyosis. Even with add-back, GnRH drugs are typically used for months rather than years, often as a bridge to surgery or menopause.
Aromatase inhibitors, which block the enzyme that converts androgens to estrogen, represent another option. A randomized trial found that aromatase inhibitors reduced adenomyoma volume by about 41% after 12 weeks, comparable to the roughly 49% reduction seen with a GnRH agonist over the same period.9PubMed. Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: a randomized controlled trial A narrative review noted that combining both drug classes reduced uterine volume by about 60% on imaging after eight weeks.10PubMed Central. The Present and the Future of Medical Therapies for Adenomyosis: A Narrative Review Aromatase inhibitors are not yet standard practice for adenomyosis and carry their own side effects, but they expand the toolkit for women who do not respond to other hormonal approaches.
Selective Progesterone Receptor Modulators
Ulipristal acetate and mifepristone are drugs that interact with progesterone receptors in a tissue-specific way, meaning they can suppress endometrial growth without mimicking full menopause. A small randomized trial of ulipristal acetate in 30 women with adenomyosis showed a significant decrease in measured blood loss during treatment, though pain and bleeding improvements were not sustained at six-month follow-up. More concerning, ulipristal was found to worsen adenomyosis in some cases, with several misdiagnosed patients experiencing increased pain and larger lesions on imaging.10PubMed Central. The Present and the Future of Medical Therapies for Adenomyosis: A Narrative Review Mifepristone has shown promise in early research through a different mechanism: it appears to trigger cell death in displaced endometrial tissue and reduce inflammatory markers linked to pain. It is affordable and has a relatively low side-effect profile, which could make it useful for the kind of long-term therapy adenomyosis demands. But the evidence remains early-stage, and neither drug is a mainstream adenomyosis treatment yet.
Uterine Artery Embolization
Uterine artery embolization, or UAE, is a minimally invasive procedure in which an interventional radiologist threads a thin catheter into the arteries feeding the uterus and injects tiny particles that block blood flow to the adenomyotic tissue. This starves the abnormal tissue of oxygen and nutrients, shrinking the uterus and relieving symptoms without surgery. A long-term follow-up study of 91 women found that 90% remained happy or very happy with the outcome, reporting no recurrence and no need for further procedures. Only about 4% required any re-intervention.11PubMed Central. Long‐term durability of uterine artery embolisation for treatment of symptomatic adenomyosis
Those numbers are encouraging, but not every study paints the same picture. An earlier long-term study of 54 women reported a lower success rate: about 57% had lasting improvement, while 19 experienced symptom relapses (mean time to relapse was about 17 months), and five eventually needed a hysterectomy.12PubMed. Long-term results of uterine artery embolization for symptomatic adenomyosis A predictive model developed from 201 patients found that factors like baseline pain severity, imaging characteristics, and the presence of co-existing endometriosis or fibroids all influenced long-term outcomes, which helps explain why results vary so widely between studies.13PubMed. Nomogram for predicting the long-term outcomes of uterine artery embolization for adenomyosis UAE preserves the uterus, but its effect on future fertility is uncertain, and most specialists still consider it primarily for women who have completed childbearing.
Focused Ultrasound and Radiofrequency Ablation
High-intensity focused ultrasound, or HIFU, uses concentrated sound waves to heat and destroy adenomyotic tissue through the skin, with no incision at all. In a study of over 220 women followed for two years, dysmenorrhea relief rates hovered around 82 to 85% from three months through two years, and heavy bleeding improved in about 79 to 81% of patients who had it before treatment.14PubMed. High-intensity focused ultrasound (HIFU) for adenomyosis: Two-year follow-up results Longer-term data suggest that combining HIFU with a hormonal IUD or a short course of GnRH agonist can improve durability of results.15PubMed. High-intensity focused ultrasound in the management of adenomyosis: long-term results from a single center HIFU is guided by either MRI or ultrasound imaging, and while it is widely available in parts of Asia and Europe, access remains limited in North America.
Radiofrequency ablation takes a different physical approach, using heat delivered through a needle or probe inserted through the vagina or abdomen to destroy targeted tissue. A review pooling data from 366 patients found that dysmenorrhea pain scores dropped by about 63% at 12 months, falling from an average of roughly 7.7 to about 2.7 on a 10-point scale. Symptom severity scores fell by about 59% over the same period.16PubMed Central. Radiofrequency Ablation for Adenomyosis Both HIFU and radiofrequency ablation are relatively new for adenomyosis, and while short-to-medium-term results look promising, data beyond five years remain sparse.
Adenomyomectomy
For women who want to preserve their uterus, particularly for future pregnancy, surgical excision of the adenomyotic tissue is an option when the disease is focal rather than spread diffusely throughout the uterine wall. The surgery can be performed through open abdominal incision (laparotomy) or laparoscopically, though the diffuse nature of adenomyosis makes it harder to identify clean margins compared with removing a fibroid. Techniques like the “triple flap method” attempt complete excision and careful uterine reconstruction.
The major concern with adenomyomectomy is what happens in a subsequent pregnancy. Case reports document uterine rupture during pregnancy after the procedure. One case involved a woman who became pregnant just one month after laparoscopic adenomyomectomy and experienced uterine rupture at the surgical site at 28 weeks.17PubMed Central. Uterine rupture during pregnancy soon after a laparoscopic adenomyomectomy A retrospective analysis of pregnancies after complete excision found that all women delivered by cesarean, and one experienced uterine rupture at 30 weeks requiring an emergency cesarean hysterectomy with substantial blood loss.18AJOG Global Reports. Possible risks and benefits of adenomyomectomy on pregnancy outcomes: a retrospective analysis A short interval between surgery and pregnancy appears to increase the risk. Most surgeons recommend waiting at least six months, and often longer, before attempting conception, and planned cesarean delivery is typically standard after adenomyomectomy.
Hysterectomy
Removing the uterus remains the only treatment that definitively eliminates adenomyosis. It is generally reserved for women with severe symptoms who have completed childbearing and have not responded adequately to other approaches. Laparoscopic hysterectomy is the preferred route when feasible. A retrospective study comparing outcomes in women with and without adenomyosis found that laparoscopic hysterectomy was safe in the adenomyosis group despite their significantly larger uterine size, with no meaningful differences in blood loss or complication rates.19PubMed Central. The effect of adenomyosis on the outcomes of laparoscopic hysterectomy
Whether the ovaries are removed along with the uterus is a separate decision that depends on your age, menopausal status, and any co-existing conditions like endometriosis. Keeping the ovaries avoids surgical menopause and its long-term consequences for bone and cardiovascular health. For many women, hysterectomy brings dramatic relief after years of failed medical therapy, but it is obviously irreversible and rules out future pregnancy.
Fertility and Pregnancy Considerations
Adenomyosis complicates fertility in multiple ways. The condition is associated with roughly triple the odds of infertility compared to women without it, and women with adenomyosis are about 2.7 times more likely to conceive through assisted reproductive technology.20PubMed. Clinical features and perinatal outcomes in women with adenomyosis For women undergoing IVF, pretreating the uterus before embryo transfer can make a real difference. A review of pretreatment strategies found that GnRH agonist therapy and levonorgestrel IUD placement are two approaches that can improve clinical pregnancy rates.21PubMed Central. Effects of pretreatment strategies on fertility outcomes in patients with adenomyosis One study of women with moderately enlarged uteri found that GnRH agonist pretreatment before frozen embryo transfer did not significantly raise the pregnancy rate itself, but it nearly tripled the live birth rate (about 47% vs. 25%) by dramatically lowering the miscarriage rate.22PubMed Central. Effect of GnRH-a pretreatment before frozen-thawed embryo transfer on pregnancy outcome of adenomyosis-associated infertile patients with 56 cm3 ≤ uterine volume ≤100 cm3
Even when pregnancy is achieved, adenomyosis raises the risk of several complications. Research has linked the condition to higher rates of preterm birth, placental abnormalities including placenta previa and placenta accreta, and excessive postpartum hemorrhage.20PubMed. Clinical features and perinatal outcomes in women with adenomyosis A narrative review added preterm premature rupture of membranes, fetal growth restriction, and preeclampsia to that list.23PubMed Central. Increased risk of obstetric complications in patients with adenomyosis: A narrative literature review These risks do not mean a healthy pregnancy is impossible, but they do mean that pregnancies in women with known adenomyosis warrant closer monitoring.
The Overlap With Endometriosis
Adenomyosis and endometriosis frequently coexist, and the overlap has real consequences for treatment planning. While adenomyosis involves endometrial-like tissue growing into the muscular wall of the uterus, endometriosis involves similar tissue growing outside the uterus entirely. The two conditions share hormonal drivers and inflammatory pathways, and a given woman’s pain may be coming from both. One long-term study of sonographic progression emphasized that the heterogeneity of clinical presentations and frequent co-occurrence of the two conditions make a personalized treatment approach essential.24PubMed Central. Sonographic and Clinical Progression of Adenomyosis and Coexisting Endometriosis: Long-Term Insights and Management Perspectives If both are present, treating only the adenomyosis while leaving endometriosis unaddressed may explain why some women do not improve as expected. This is one reason thorough imaging matters before settling on a treatment plan.
Mental Health and the Hidden Cost of Symptoms
Living with chronic pelvic pain and unpredictable heavy bleeding takes a toll beyond the physical. Research comparing women with adenomyosis to those with uterine fibroids found a significant correlation between quality of life, anxiety, and depression: women with worse quality of life were substantially more likely to have symptoms of anxiety and depression, and the relationship ran in both directions.25PubMed Central. Higher Risk of Anxiety and Depression in Women with Adenomyosis as Compared with Those with Uterine Leiomyoma The economic impact is measurable too. A comparative study found that women with adenomyosis lost about 38% of their overall work productivity, compared to roughly 12% in controls, and experienced activity impairment exceeding 55%. The estimated yearly indirect cost difference was over €5,000 per patient.26PubMed Central. Impact of Adenomyosis on Women’s Psychological Health and Work Productivity: A Comparative Cross-Sectional Study
These findings argue for treating adenomyosis proactively rather than waiting to see if symptoms become unbearable. Lifestyle interventions including dietary modification, physical activity, yoga, and transcutaneous electrical nerve stimulation have shown potential benefits for pelvic pain management in early research, though the evidence base remains limited and methodologically mixed.27PubMed Central. What is the Evidence on Lifestyle Interventions for the Symptom Management of Pelvic Pain in Women With Endometriosis or Adenomyosis? A Scoping Review They are unlikely to replace medical therapy for moderate or severe disease, but as part of a broader management plan that includes effective medication or a procedure, they can help reclaim some of the quality of life the condition erodes.